The overall risk of RS was moderate and temporally confined within a few years from the index event, and the risk of RS was lower for those patients who used statins after the index event than for nonusers.
Abstract
Objective
Preclinical evidence supports the role of statins as antiepileptogenic agents. In this study, we investigated the risk of remote unprovoked seizures (RS) according to the use of statin therapy in a cohort of first-ever status epilepticus (SE) survivors.
Methods
Retrospective analysis was made of adult patients (age ≥ 14 years) with a first SE who were consecutively and prospectively admitted to the Modena Academic Hospital, Italy (September 2015-December 2023) and included in the Modena Status Epilepticus Registry. Kaplan-Meier survival analyses were used to calculate the probability of RS following the index SE event, whereas Cox proportional hazard and competing risk regression models were used to assess predictors of RS occurrence.
Results
A total of 314 patients were included (mean age = 70 years, 63% females). The statin-exposed cohort included both patients already receiving statins before SE (n = 68) and patients in whom statin administration was started during the hospitalization (n = 18). Atorvastatin (69/86, 80%) was the most frequently prescribed statin. Overall, 67 patients (21.3%) developed RS (mean follow-up = 31.5 months). Cumulative probability of RS occurrence was 16%, 23%, and 32% at 12 months, 2 years, and 5 years after SE, respectively. Median time from index event to first RS was 6.9 months (interquartile range = 11.6 months). Cumulative probability of RS was significantly lower in statin users compared to nonusers (log-rank p = .038). After adjusting for confounders, the risk of RS was lower for those patients who used statins after the index event (hazard ratio = .48, 95% confidence interval [CI] = .26-.90, p = .023).
Significance
The overall risk of RS was moderate and temporally confined within a few years from the index event. Statin exposure was associated with a lower incidence of RS. Our findings expand knowledge regarding a possible antiepileptogenic role of statins after SE and support further studies in this field.
Even in structural etiologies, ASySs bear a relatively low risk of later unprovoked seizures, and there is still no evidence favoring prolonged ASM treatments, which may help preventing ASM overtreatment and guide counseling on driving eligibility.
Hannah Traben, Julia Herzig-Nichtweiß, L. Langenbruch et al.· Epilepsia· 0 citations
Elevated baseline D-dimer levels were independently associated with an increased risk of PSE within one year after AIS, and as a routinely available biomarker, D-dimer may inform risk assessment in acute stroke units.
BACKGROUND
To determine seizure recurrence rates and independent risk factors following antiseizure medication (ASM) withdrawal in pediatric epilepsy, and integrate these findings into a personalized web-based clinical decision support system (CDSS).
METHODS
In this prospective cohort study, 318 pediatric epilepsy pa...
Gül Yücel, A. Arslan, Işınsu Bıçakcıoğlu et al.· Seizure· 0 citations
Objective: To determine the prevalence and predictors of drug-resistant epilepsy among patients with epilepsy.
Methodology: A retrospective observational study was conducted at the Neurology Department of Liaquat National Hospital, Karachi, for the period from November, 2024 to October, 2025. Patients with epilepsy wer...
Saba Zaidi, Umer Barry, Malaika Ali· Pakistan Journal of Medical...· 0 citations